SCHEMBL5007409

SCHEMBL5007409

O=C(O)C1CCCN(C2CC(c3ccccc3)C2)C1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.51
AKR1C1 Q04828 1/20 0.51
AGTR2 P50052 10/20 0.51
ALDH1A1 P00352 2/20 0.50
HTR2A P28223 2/20 0.48
HRH1 P35367 2/20 0.48
HTR2C P28335 1/20 0.48
HTR2B P41595 1/20 0.48
LTA4H P09960 1/20 0.48
SLC6A1 P30531 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
TSHR P16473 1/20 0.46
NFKB1 P19838 1/20 0.46
CYP2C19 P33261 1/20 0.46
HSD17B10 Q99714 1/20 0.46
LMNA P02545 1/20 0.46
NOTUM Q6P988 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1587410 0.91 AKR1C3 (0.54) AKR1C3AKR1C1AGTR2HTR2AHRH1
SCHEMBL5009505 0.89 ALDH1A1 (0.48) AGTR2ALDH1A1HTR2AHRH1HTR2C
SCHEMBL6373468 0.88 CYP2D6 (0.59) AKR1C3AKR1C1AGTR2ALDH1A1HTR2A
SCHEMBL5004640 0.87 ALDH1A1 (0.50) AGTR2ALDH1A1HTR2AHRH1HTR2C
SCHEMBL444560 0.83 AKR1C3 (0.56) AKR1C3AKR1C1AGTR2HTR2AHRH1
SCHEMBL5004398 0.82 ALDH1A1 (0.48) ALDH1A1HTR2AHRH1HTR2CHTR2B
SCHEMBL447356 0.82 SLC18A3 (0.50) AGTR2ALDH1A1LTA4HCYP1A2CYP2D6
SCHEMBL5004123 0.81 OPRM1 (0.44) ALDH1A1HTR2AHRH1HTR2CHTR2B
SCHEMBL5007457 0.79 SLC6A2 (0.49) AKR1C3ALDH1A1HTR2AHRH1HTR2C
SCHEMBL5004623 0.78 KDM2B (0.54) ALDH1A1SLC6A1CYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 AKR1C3 1826/4885AKR1C1 2592/4885AGTR2 2698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.